News Immunomedics wows ESMO with breast cancer data reveal Immunomedics has revealed the trial data that convinced Gilead to stage a
News Gilead pays $21bn for Immunomedics ahead of breast cancer tr... Gilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer blockbuster Trodelvy, days before survival data is due to be reveal
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
